Company
Every investor coverage indicates participated in a round US COPD Foundation raised.
Companies US COPD Foundation acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Ruth Tal-Singer | President and Chief Scientific Officer (former) | Brandon Capital portfolio (Tue 22 Jun 2021), Brandon Capital portfolio (Wed 16 Jun 2021), Brandon BioCatalyst portfolio (Wed 16 Jun 2021), Brandon Capital portfolio (Tue 15 Jun 2021), Brandon BioCatalyst portfolio (Tue 15 Jun 2021) |
Stories naming US COPD Foundation. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne-based ENA Respiratory announced US patent allowances covering its TLR2 agonist platform and a COPD treatment method, strengthening IP protection for its INNA-051 nasal spray candidate now in Phase II testing.
Melbourne biotech ENA Respiratory has begun dosing volunteers in a mid-stage trial of its INNA-051 antiviral spray, aimed at limiting common viral illnesses in at-risk groups.
Melbourne pharmaceutical company ENA Respiratory has received US$5 million from California's Flu Lab to advance clinical testing of its nasal immune-boosting antiviral candidate INNA-051.
Melbourne's ENA Respiratory has won a further US$3.18 million US Defense Department contract to widen its INNA-051 Phase Ib trial to younger adults, extending the US$8.18 million the agency had already committed.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·enarespiratory.com
Australian biotech ENA Respiratory raised funding led by Brandon Capital and Minderoo Foundation to advance its Covid-19 nasal spray toward the clinic, and appointed Ruth Tal-Singer to its board.
ENA Respiratory secured up to AU$32 million, co-led by Brandon Capital Partners and Minderoo Foundation with Uniseed, to advance its INNA-051 nasal spray, and appointed Ruth Tal-Singer to its board.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·SmartCompany·SmartCompany